Old Web
English
Sign In
Acemap
>
authorDetail
>
Sarah Miyata
Sarah Miyata
Northwestern University
Medicine
Immunology
ABVD
Internal medicine
Pathology
8
Papers
120
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease.
2008
American Journal of Clinical Pathology
Katalin Kelemen
LoAnn Charlotte Peterson
Irene B. Helenowski
Charles Lewis Goolsby
Borko Jovanovic
Sarah Miyata
Olivia Aranha
Steven T. Rosen
Jane N. Winter
Beverly P. Nelson
Leo I. Gordon
Andrew M. Evens
Show All
Source
Cite
Save
Citations (42)
Survival of CD23-positive (CD23+) mantle cell lymphoma (MCL) compared to classic CD23-negative (CD23-) MCL: Biologic correlates and clinical outcomes in a 10-year analysis
2007
Journal of Clinical Oncology
Andrew M. Evens
Katalin Kelemen
Olivia Aranha
Borko Jovanovic
Sarah Miyata
Beverly P. Nelson
Charles Lewis Goolsby
S. T. Rosen
Jane N. Winter
LoAnn Charlotte Peterson
Leo I. Gordon
Show All
Source
Cite
Save
Citations (1)
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
2007
British Journal of Haematology
Andrew M. Evens
Jeffrey Cilley
Taylor Ortiz
Mrinal Gounder
Nanjiang Hou
Alfred W. Rademaker
Sarah Miyata
Kara Catsaros
Connie Augustyniak
Charles L. Bennett
Martin S. Tallman
Daina Variakojis
Jane N. Winter
Leo I. Gordon
Show All
Source
Cite
Save
Citations (65)
Lack of necessity of granuloctye-colony stimulating factor (GF) in Hodgkin's disease (HD) treated with ABVD
2006
Journal of Clinical Oncology
Andrew M. Evens
Jeffrey Cilley
Mrinal Gounder
T. Ortiz
Sarah Miyata
K. Catsaros
Alfred W. Rademaker
Martin S. Tallman
Jane N. Winter
Leo I. Gordon
Show All
Source
Cite
Save
Citations (0)
1